• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Twist Bioscience’s US$17.05 Million Class Action Settlement Reshape Risk Perceptions for TWST Investors?

    Simply Wall St·08/02/2026 08:15:16
    語音播報
    • Twist Bioscience Corporation recently held a hearing on a proposed US$17,050,000 cash settlement to resolve a securities class action covering purchasers of its common stock between December 20, 2018 and November 15, 2022, as well as participants in its December 2020 offering.
    • The proposed settlement, if fully approved, would close off ongoing litigation risk for a large group of past investors and clarify Twist Bioscience’s legal exposure tied to earlier capital-raising activities.
    • We’ll now examine how resolving a US$17,050,000 class action settlement could influence Twist Bioscience’s investment narrative and perceived risk profile.

    Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

    Twist Bioscience Investment Narrative Recap

    To own Twist Bioscience, you need to believe its synthetic DNA platform can scale into a broader toolkit for genomics and drug discovery, despite ongoing losses. The proposed US$17,050,000 securities class action settlement, if approved, looks more like a clean up of legacy issues than a change to near term operational catalysts, with the main risk still centered on unprofitability and potential future capital needs.

    Against this legal backdrop, Twist’s recent Q2 2026 update remains more central to the near term story, with revenue of US$110.72M and a net loss of US$44.02M underscoring both the appeal of its growing top line and the financial risk of funding expansion while still far from profitability.

    Yet behind the growth story, investors should also be aware of the risk that persistent losses could eventually force Twist to...

    Read the full narrative on Twist Bioscience (it's free!)

    Twist Bioscience's narrative projects $666.9 million revenue and $113.3 million earnings by 2029.

    Uncover how Twist Bioscience's forecasts yield a $92.50 fair value, in line with its current price.

    Exploring Other Perspectives

    TWST 1-Year Stock Price Chart
    TWST 1-Year Stock Price Chart

    Before this settlement news, the most optimistic analysts were assuming revenue could reach about US$715.3M and earnings US$128.5M by 2029, a far more aggressive path than consensus, but those expectations may be tested once you factor in ongoing legal and execution risks.

    Explore 4 other fair value estimates on Twist Bioscience - why the stock might be worth over 2x more than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Contemplating Other Strategies?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.